Integrated drug discovery at Axxam is delivered through DiscoveryMAXX, our fully coordinated target-to-lead platform designed to translate biological insight and AI-driven predictions into experimentally validated drug candidates. DiscoveryMAXX combines multidisciplinary scientific expertise with advanced assay technologies to ensure continuity, data quality, and efficient decision making across early discovery.

A central strength of DiscoveryMAXX is the wet lab validation of AI-enabled data. We support the transition from in silico target, pathway, and compound predictions to experimental confirmation through tailored biochemical and cellular assays. This enables functional validation of hypotheses generated by artificial intelligence and strengthens biological confidence before progression into screening and optimization.

Our integrated workflow supports all key phases of early discovery, from target and pathway assessment to hit identification and lead optimization, including emerging areas such as RNA biology and novel target classes. Transparent communication, consistent reporting, and flexible collaboration ensure seamless coordination across disciplines and project stages, contributing to the de-risking of discovery programs.